Evaluate regulatory compliance, client concentration, lab partnerships, and revenue quality before closing on a drug testing collection or MRO business.
Acquiring a drug testing services company requires scrutiny well beyond standard financial review. Buyers must validate DOT and SAMHSA regulatory standing, isolate true collection margin from pass-through lab revenue, and assess whether client relationships are contractually anchored or dependent on the departing owner. This checklist guides buyers through five critical due diligence categories specific to the drug testing industry, helping you identify deal-killers early and structure a defensible acquisition.
Verify the business holds all required federal and state certifications with a clean enforcement history before proceeding to LOI.
Confirm all collector certifications and DOT qualifications are current and transferable to a new owner.
Expired or non-transferable certifications can halt operations immediately post-close and trigger DOT compliance violations.
Red flag: Any collector certifications lapsed in the past 24 months or tied to the seller personally with no transfer pathway.
Obtain five-year DOT and SAMHSA audit history including findings, corrective actions, and resolution documentation.
Unresolved audit findings or repeat violations signal systemic compliance failure that survives ownership changes.
Red flag: Open DOT consent orders, pending SAMHSA investigations, or undisclosed chain-of-custody violations on record.
Review all state occupational health and drug testing program licenses for current standing and renewal timelines.
State licensing gaps can restrict service delivery in key employer markets without warning after acquisition.
Red flag: Licenses operating in expired or conditional status in states representing more than 10% of revenue.
Confirm HIPAA compliance policies and data handling procedures for specimen results and employee medical records.
HIPAA violations in drug testing carry significant civil penalties and can damage employer client trust irreparably.
Red flag: No formal HIPAA policy, undocumented result-sharing procedures, or prior breach notifications issued to clients.
Analyze the durability and diversity of the employer client base to assess post-close revenue risk and retention probability.
Request full client roster with annualized revenue, contract terms, and renewal history by employer segment.
Undocumented or informal client relationships create immediate churn risk when the seller exits the business.
Red flag: Any single employer account exceeding 20% of total collections volume with no written multi-year contract in place.
Calculate client retention rate over three years across transportation, construction, healthcare, and government segments.
Segment-level retention reveals whether churn is isolated or systemic across specific regulated industries.
Red flag: Overall retention below 85% annually or churn concentrated in DOT-regulated transportation accounts.
Identify all month-to-month purchase order relationships and quantify associated revenue at risk post-close.
Purchase order clients can cancel without notice, creating immediate revenue gaps if the seller relationship dissolves.
Red flag: More than 30% of revenue derived from informal purchase orders with no executed master service agreements.
Confirm contract assignability and change-of-control provisions for the top ten employer accounts by revenue.
Non-assignable contracts require client re-signing, delaying revenue certainty and enabling competitor poaching.
Red flag: Multiple top-ten contracts containing change-of-control termination rights without client consent requirements.
Isolate true collection margin from pass-through lab and MRO charges to understand the business's actual earnings power.
Recast three years of financials separating collection fees, MRO services revenue, and pass-through lab charges.
Pass-through lab revenue inflates top-line while contributing near-zero margin, distorting EBITDA calculations significantly.
Red flag: Seller presenting blended gross margins without separating pass-through lab costs from proprietary service revenue.
Verify EBITDA add-backs including owner compensation, personal expenses, and above-market related-party transactions.
Inflated add-backs overstate normalized earnings and directly compress the true return on acquisition price.
Red flag: Add-backs exceeding 25% of reported EBITDA or unsupported by documentation and market-rate benchmarks.
Analyze monthly revenue trends to identify seasonality, volume spikes, and dependency on court-ordered testing programs.
Court-ordered testing volumes can shift unpredictably with local judicial policy changes and diversion program funding cuts.
Red flag: Revenue variance exceeding 30% between peak and trough months without recurring contractual volume commitments.
Confirm billing and collections processes including DSO, write-off rates, and any disputed employer invoices outstanding.
Poor collections discipline in drug testing often signals informal client relationships and weak contract enforcement.
Red flag: Days sales outstanding exceeding 60 days or write-off rates above 3% of gross billing on employer accounts.
Evaluate third-party laboratory and Medical Review Officer relationships for pricing stability, exclusivity risk, and continuity.
Review all SAMHSA-certified lab agreements including pricing schedules, volume commitments, and termination provisions.
Lab contract termination or repricing can eliminate margin on collection services with little operational recourse.
Red flag: Primary lab agreement containing unilateral termination rights exercisable in fewer than 90 days without cause.
Assess MRO vendor agreements or in-house MRO qualifications including physician credentials and caseload capacity.
MRO services generate recurring high-margin revenue that is lost if the reviewing physician departs post-close.
Red flag: In-house MRO is the seller personally with no succession plan, employment agreement, or licensed backup reviewer.
Identify exclusivity clauses or volume minimums in lab contracts that restrict competitive renegotiation post-acquisition.
Volume minimums below post-close collection levels trigger financial penalties that compress acquisition-year margins.
Red flag: Volume commitment thresholds within 15% of trailing twelve-month collection volumes with penalty clauses attached.
Confirm change-of-control provisions in all third-party administrator and collector network agreements.
TPA agreements that terminate on ownership change disrupt employer client servicing and revenue continuity immediately.
Red flag: TPA agreements requiring counterparty consent to assign with no pre-negotiated change-of-control consent on file.
Assess operational infrastructure, technology capability, and owner dependency to evaluate post-close continuity risk.
Evaluate LIMS and chain-of-custody software capabilities including electronic COC, result reporting, and HR integrations.
Paper-based chain-of-custody operations are competitively obsolete and signal near-term technology capital expenditure needs.
Red flag: Business still operating on paper chain-of-custody forms with no electronic reporting integration for employer clients.
Document which employer accounts, MRO reviews, and compliance functions are managed solely by the seller.
Owner-dependent client relationships dissolve quickly post-close if no structured transition or earnout is in place.
Red flag: Seller managing more than three top-ten accounts personally with no documented account manager or backup contact.
Review standard operating procedures for specimen collection, custody handling, and non-negative result escalation.
Undocumented SOPs create regulatory and liability exposure when trained staff depart or new locations are added.
Red flag: No written SOPs exist for chain-of-custody or the seller cannot produce documented collection site training records.
Assess mobile collection fleet condition, collection site lease terms, and technology readiness for oral fluid testing.
Capital-intensive fleet replacements or expiring site leases create unplanned post-close costs that erode acquisition returns.
Red flag: Fleet vehicles with more than 150,000 miles or collection site leases expiring within 12 months of projected close.
Find Drug Testing Services Businesses For Sale
Vetted targets with diligence packages — skip the cold search.
Request a revenue recast from the seller that isolates three line items: collection and handling fees, MRO service fees, and pass-through laboratory charges billed at cost. True gross margin in drug testing services typically runs 40–65% on collection and MRO revenue but near zero on pass-through lab charges. If the seller cannot produce this breakdown, engage a healthcare-focused Quality of Earnings provider to reconstruct it from billing records before issuing a final offer.
The business must transfer DOT-qualified collector certifications for all active collection sites, SAMHSA-certified lab service agreements, any state occupational health or drug testing program licenses, and MRO physician credentials if MRO is performed in-house. Confirm each certification is held by the entity being acquired rather than by the seller personally, and verify that lab and TPA agreements contain assignment provisions or pre-negotiated change-of-control consent before signing a purchase agreement.
For drug testing businesses where the seller manages key employer accounts or performs MRO reviews personally, structure an earnout tied to client revenue retention at 90 and 180 days post-close rather than total revenue growth. A common structure pairs an SBA 7(a) loan at 85–90% of purchase price with a seller note of 5–10% held for 24 months, with the earnout releasing in tranches if named accounts remain active and collections volume holds within 10% of trailing twelve-month levels.
Drug testing service businesses in the $1M–$5M revenue range typically trade at 3.5x–6.0x trailing twelve-month EBITDA. Businesses commanding multiples at the high end carry diversified employer contract bases with no single account above 15% of revenue, electronic chain-of-custody technology, DOT consortium management revenue, and clean five-year regulatory histories. Businesses with owner dependency, paper-based operations, or significant pass-through revenue compression tend to close in the 3.5x–4.5x range with stronger seller note and earnout components.
More Drug Testing Services Guides
More Due Diligence Checklists
Stop cold-searching. Find signal-scored Drug Testing Services targets with seller motivation already identified.
Create your free accountNo credit card required
For Buyers
For Sellers